Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
Phase 2
Completed
- Conditions
- Pemphigus
- Registration Number
- NCT00010413
- Lead Sponsor
- Johns Hopkins University
- Brief Summary
OBJECTIVES:
I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
- Detailed Description
PROTOCOL OUTLINE: Patients receive cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) beginning on day 10 and continuing until blood counts recover.
Patients are followed monthly for 6 months, every 2 months for 6 months, every 4 months for a year, and then annually thereafter.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Johns Hopkins University School of Medicine
🇺🇸Baltimore, Maryland, United States
Johns Hopkins University School of Medicine🇺🇸Baltimore, Maryland, United States